Skip to main content

Postoperative Cognitive Dysfunction

0
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Eppendorf
EppendorfGermany - Hamburg
2 programs
Study of Depressive Symptoms Predicting Postoperative Cognitive DysfunctionN/A1 trial
monitoring and non-medical prophylaxis of deliriumN/A1 trial
Active Trials
NCT02210312Completed300Est. Oct 2018
NCT03060174Completed638Est. May 2021
Cognition Therapeutics
Cognition TherapeuticsPA - Pittsburgh
1 program
Cog-Train InterventionN/A1 trial
Active Trials
NCT02053207Unknown10Est. Dec 2018
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Goal directed therapyN/A1 trial
Active Trials
NCT04246320Completed7Est. Aug 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Angeles TherapeuticsGoal directed therapy
Cognition TherapeuticsCog-Train Intervention
EppendorfStudy of Depressive Symptoms Predicting Postoperative Cognitive Dysfunction
Eppendorfmonitoring and non-medical prophylaxis of delirium

Clinical Trials (4)

Total enrollment: 955 patients across 4 trials

NCT04246320Angeles TherapeuticsGoal directed therapy

Taking Brain Monitoring to the Next Level

Start: Jan 2020Est. completion: Aug 20227 patients
N/ACompleted
NCT02053207Cognition TherapeuticsCog-Train Intervention

Feasibility Study of Preoperative Cognitive Training in Cardiac Surgical Patients

Start: Jan 2018Est. completion: Dec 201810 patients
N/AUnknown
NCT02210312EppendorfStudy of Depressive Symptoms Predicting Postoperative Cognitive Dysfunction

Study of Depressive Symptoms Predicting Postoperative Cognitive Dysfunction

Start: May 2014Est. completion: Oct 2018300 patients
N/ACompleted
NCT03060174Eppendorfmonitoring and non-medical prophylaxis of delirium

Study of Prevention of Postoperative Delirum to Reduce Incidence of Postoperative Cognitive Dysfunction

Start: May 2014Est. completion: May 2021638 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.